コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 p differences (ie, lower vs higher Karnofsky performance status).
2 ied by presence of visceral disease and ECOG performance status.
3 (FHSI-8), and time to deterioration in ECOG performance status.
4 ntre, site of disease, resection status, and performance status.
5 ufficiency, portal vein thrombosis, and poor performance status.
6 lure, survival, and time to deterioration in performance status.
7 Randomisation was stratified by hospital and performance status.
8 ranial control, survival, or preservation of performance status.
9 OS was related to prior ablation and higher performance status.
10 noma, and Eastern Cooperative Oncology Group performance status.
11 , planned number of chemotherapy cycles, and performance status.
12 ality of life for elderly patients with good performance status.
13 on was stratified by disease extent and ECOG performance status.
14 She has remained active with an excellent performance status.
15 d at randomisation by disease stage and ECOG performance status.
16 ing to number of previous therapies and ECOG performance status.
17 live at the 1-year time point with excellent performance status.
18 ous lineage with adequate organ function and performance status.
19 ffect more pronounced in patients with lower performance status.
20 were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per
21 ients with metastatic colorectal cancer (WHO performance status 0 or 1) with liver metastases not sui
24 an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, previously treated with at le
26 T1-T2, N2a-N3 M0 or T3-T4, N0-N3 M0; Zubrod performance status 0 or 1; age at least 18 years; and ad
27 toid MPM (Eastern Cooperative Oncology Group performance status 0 to 1), stratified by histology (epi
28 rmed SCLC (limited or extensive disease) and performance status 0 to 3 were randomly assigned to rece
29 pausal women aged at least 50 years with WHO performance status 0-1 and hormone receptor-positive, op
30 ioid malignant pleural mesothelioma and ECOG performance status 0-1 were randomly assigned 1:1 via an
32 an Eastern Cooperative Oncology Group (ECOG) performance status 0-1, adequate organ function, and had
33 eated, were aged 18 years or older, had ECOG performance status 0-1, and required further treatment a
34 or older, Eastern Cooperative Oncology Group performance status 0-1, metastatic or locally advanced p
35 le patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (dura
36 ysphagia, Eastern Cooperative Oncology Group performance status 0-2, and adequate haematological and
37 igible men aged 18 years and older, with WHO performance status 0-2, low-risk or intermediate-risk pr
38 ancer requiring radioactive iodine ablation (performance status 0-2, tumour stage T1-T3 with the poss
40 III/IV) or colorectal (stage IV) cancer, WHO performance status 0-3, and at least 3 months life expec
42 At multivariable analysis, age (< 60 years), performance status (0 v >/= 1), size of the largest lesi
43 3-T4), N category (N0-N2a vs N2b-N3), Zubrod performance status (0 vs 1), and tobacco smoking history
45 was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or a
46 II NSCLC (Eastern Cooperative Oncology Group performance status, 0 to 1) received dose-escalated RT t
47 rgin status, positive lymph node status, WHO performance status 1, and R1-direct positive superior me
48 y hospital site, site of primary tumour, WHO performance status, 16-week CT scan result, number of me
49 =0.0188), Eastern Cooperative Oncology Group performance status 3-4 (2.92 [2.13-3.93]; p<0.0001) and
51 radiographically measurable GCTB, Karnofsky performance status 50% or higher (Eastern Cooperative On
52 IB histologically confirmed NSCLC, Karnofsky performance status 70 to 100, and 6-month prediagnosis w
53 ne, T-pretreated patients had overall poorer performance status, a higher prevalence of bone metastas
54 addition to tumor burden, liver function and performance status; additional parameters including tumo
56 te analysis, several baseline factors (e.g., performance status, age, sex, number of organ sites with
57 the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, an
58 frailty and predicts outcomes independent of performance status among older patients with blood cance
59 CCI cohort had persistent severely impaired performance status and a much higher mortality (41.4%) t
60 d by including additional covariates such as performance status and albumin, yielding AUCs as high as
62 ad not been previously treated and had a WHO performance status and American Society of Anesthesiolog
65 tified by Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutini
68 re more appropriate for patients with a poor performance status and low to moderate symptom burden.
70 atified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pem
71 resource utilization, and long-term physical performance status and survival were compared among AKI
75 e, with stratification by tumour origin, WHO performance status, and previous somatostatin analogue t
76 NA, high WB-MATV, body mass index < 30, poor performance status, and short time since diagnosis).
77 s >16 years) or Lansky (patients <=16 years) performance status; and had received no previous chemoth
78 independent t tests stratified by Karnofsky performance status; and responsiveness to change over ti
79 ogenase, number/sites of involvement, stage, performance status) are widely used: the International P
81 l region, Eastern Cooperative Oncology Group performance status at baseline, and visceral metastasis.
84 ge, a modified disease risk index, Karnofsky performance status, donor age, HLA match, sex match, cyt
85 marrow, liver and kidney function, and good performance status (Eastern Cooperative Oncology Group [
86 se/higher Eastern Cooperative Oncology Group performance status (ECOG PS) >=2, stage III or IV diseas
87 disease, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, and following manageme
88 ents were over 65 (86%), female (52%), had a performance status (ECOG-PS) of 0 or 1 (57%), were at nu
90 versus EGFR-TKI, WBRT versus EGFR-TKI, age, performance status, EGFR exon 19 mutation, and absence o
91 removal due to death/deterioration were poor performance status, encephalopathy, diabetes, high Model
92 the same clinical variables (age, Karnofsky Performance Status, extent of resection, and neurologic
93 ther with clinical variables (age, Karnofsky Performance Status, extent of resection, and neurologica
94 etween 1985 and 2005: patient age, Karnofsky Performance Status, extracranial metastases, and number
95 ed on tumor number, size, vascular invasion, performance status, functional liver reserve, and the pr
96 ty rates for the low, intermediate, and high performance status groups were 23% (36/159), 11% (55/489
97 erentiation, positive lymph node status, WHO performance status >=1, maximum tumor size, and R1-direc
98 risk of patient or graft failure were a poor performance status (hazard ratio [HR], 1.64; 1.19-2.26),
100 .799 [95% CI 0.545-1.171]; p=0.238) and ECOG performance statuses (HR 1.082 [95% CI 0.639-1.832]; p=0
102 more, 30-day home time reclassified hospital performance status in ~30% of hospitals versus 30-day RS
103 Reasonable options for patients with poor performance status include hypofractionated radiotherapy
104 advanced age, lower body mass index, poorer performance status, increased number of metastatic sites
107 functional status, as measured by Karnofsky Performance Status (KPS), and liver transplant (LT) cost
110 identified age at least 57 years, Karnofsky performance status lower than 90%, platelet count lower
111 alysis for T-pretreated patients were poorer performance status, lower cumulative administered activi
112 ents with Eastern Cooperative Oncology Group performance status </= 2 and two or more prior systemic
113 s, Eastern Cooperative Oncology Group (ECOG) performance status <=2) with confirmed metastatic castra
114 l region, Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic
115 exercises on improving swallowing function, performance status, mouth opening, risk of aspiration/pe
116 ) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and centrally confirmed, me
117 lder with Eastern Cooperative Oncology Group performance status of 0 or 1 and histologically confirme
118 lder with Eastern Cooperative Oncology Group performance status of 0 or 1 and measurable disease as d
119 ) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely rese
122 ma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (1:1
123 ma and an Eastern Cooperative Oncology Group performance status of 0 or 1 who had received at least t
124 , with an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate end-organ fun
125 an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ functio
126 PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAF(V600)
127 a, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had received previous
128 ation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
129 ancer, an Eastern Cooperative Oncology Group performance status of 0 or 1, and received no previous c
130 disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously rec
131 myeloma, Eastern Cooperative Oncology Group performance status of 0 or 1, and who were treatment nai
132 an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, at least one measurable le
133 ), had an Eastern Cooperative Oncology Group performance status of 0 or 1, had received no more than
134 r with an Eastern Cooperative Oncology Group performance status of 0 or 1, HER2-positive, operable, l
135 ears with Eastern Cooperative Oncology Group performance status of 0 or 1, ipilimumab-naive histologi
136 l review, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at leas
137 tastases, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at leas
138 ction, an Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at leas
139 an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, MET-positive tumours (>/=2
140 sting, an Eastern Cooperative Oncology Group performance status of 0 or 1, one or more previous lines
141 , with an Eastern Cooperative Oncology Group performance status of 0 or 1, who had progressed after a
142 ally) and Eastern Cooperative Oncology Group performance status of 0 or 1, who had unlimited previous
143 , with an Eastern Cooperative Oncology Group performance status of 0 or 1, who were scheduled to have
144 ients were aged at least 18 years, had a WHO performance status of 0 or 1, with histologically or cyt
157 an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; (B) BRAF(V600E)-positive,
158 th previous local brain therapy, and an ECOG performance status of 0 or 1; (C) BRAF(V600D/K/R)-positi
159 ut previous local brain therapy, and an ECOG performance status of 0 or 1; and (D) BRAF(V600D/E/K/R)-
160 erapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; and a formalin-fixed, para
161 ation; an Eastern Cooperative Oncology Group performance status of 0 or 1; and had previously receive
164 S who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function
165 iteria included a Gynecologic Oncology Group performance status of 0 to 2 and no history of clinicall
166 mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or po
167 mCRPC and Eastern Cooperative Oncology Group performance status of 0 to 2 were randomly assigned 1:1:
168 harboring an EGFR-sensitizing mutation and a performance status of 0 to 2 who were planned to receive
170 disease, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and left ventricular e
172 %) had an Eastern Cooperative Oncology Group performance status of 0, and the median age was 61 years
173 ty had an Eastern Cooperative Oncology Group performance status of 0-1 (142 [72%] of 196 patients), w
174 ts had an Eastern Cooperative Oncology Group performance status of 0-1 and had no previous treatment
175 s with an Eastern Cooperative Oncology Group performance status of 0-1 recruited between June 20, 200
176 atients with HER2-negative AEGC and a Zubrod performance status of 0-1 were evaluated prospectively f
177 ma and an Eastern Cooperative Oncology Group performance status of 0-1) received cemiplimab 3 mg/kg i
178 ancer, an Eastern Cooperative Oncology Group performance status of 0-1, and a history of smoking expo
179 r status, Eastern Cooperative Oncology Group performance status of 0-1, and adequate bone marrow, hep
180 n, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adequate haematological a
181 baseline Eastern Cooperative Oncology Group performance status of 0-1, and disease progression on or
182 or older, Eastern Cooperative Oncology Group performance status of 0-1, and documented disease progre
183 f less than the upper limit of normal, had a performance status of 0-1, and had adequate organ functi
184 lable, an Eastern Cooperative Oncology Group performance status of 0-1, and measurable disease by Res
185 baseline Eastern Cooperative Oncology Group performance status of 0-1, and who were refractory or in
187 ancer; an Eastern Cooperative Oncology Group performance status of 0-1; and had relapsed after or wer
188 site amenable to repeated biopsies; an ECOG performance status of 0-1; and progressive disease after
189 ressed in the previous 6 months; had an ECOG performance status of 0-1; life expectancy of more than
191 ts had an Eastern Cooperative Oncology Group performance status of 0-2 and could have received previo
192 s with an Eastern Cooperative Oncology Group performance status of 0-2 and oestrogen receptor-positiv
193 an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 recruited from 146 academic or
194 ctable colorectal liver metastases and a WHO performance status of 0-2 were randomly assigned (1:1) t
195 er and an Eastern Cooperative Oncology Group performance status of 0-2 were randomly assigned (1:1:1)
196 y with an Eastern Cooperative Oncology Group performance status of 0-2 were recruited, centrally rand
197 , with an Eastern Cooperative Oncology Group performance status of 0-2, a life expectancy of at least
199 ), Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, age of 18 years or older, and
200 g cancer, Eastern Cooperative Oncology Group performance status of 0-2, and adequate pulmonary functi
201 s, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and at least two of the three
202 tic, with Eastern Cooperative Oncology Group performance status of 0-2, and did not have high-risk le
203 n, had an Eastern Cooperative Oncology Group performance status of 0-2, and had measurable disease at
204 ancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received previous sys
205 ancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received up to two pr
206 s, had an Eastern Cooperative Oncology Group performance status of 0-2, and had sufficient tumour tis
207 o have an Eastern Cooperative Oncology Group performance status of 0-2, and had to have previously re
208 ts had an Eastern Cooperative Oncology Group performance status of 0-2, and previous cancer treatment
209 aemia, an Eastern Cooperative Oncology Group performance status of 0-2, and were at high risk of dise
210 o have an Eastern Cooperative Oncology Group performance status of 0-2, left ventricular ejection fra
211 r with an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy of more than
212 sease, an Eastern Cooperative Oncology Group performance status of 0-2, who received one to three pre
222 ma and an Eastern Cooperative Oncology Group performance status of 0-3 were randomly assigned to rece
224 ears, had Eastern Cooperative Oncology Group performance status of 1 or less, and had Child-Pugh A li
225 r, had an Eastern Cooperative Oncology Group performance status of 1 or less, had adequate organ func
226 3-15.28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1
228 , with an Eastern Cooperative Oncology Group performance status of 2 or less (<=1 for phase 1 only) f
229 d with an Eastern Cooperative Oncology Group performance status of 2 or less had tumour biopsies test
230 margin), Eastern Cooperative Oncology Group performance status of 2 or less, and life expectancy of
231 s, had an Eastern Cooperative Oncology Group performance status of 2 or less, and received at least o
232 tment, an Eastern Cooperative Oncology Group performance status of 2 or less, and received no previou
233 , with an Eastern Cooperative Oncology Group performance status of 2 or less, and were given umbralis
234 , with an Eastern Cooperative Oncology Group performance status of 2 or less, and with adequate end-o
235 erapy, an Eastern Cooperative Oncology Group performance status of 2 or less, had measurable disease,
236 eloma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received one to
237 phoma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received two to
241 eview; were aged 18 years or older; had ECOG performance status of 2 or less; had bulky stage I or st
242 , with an Eastern Cooperative Oncology Group performance status of 2 or lower, and adequate organ and
243 of SCLC, Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease as
244 nd had an Eastern Cooperative Oncology Group performance status of 2 or lower, were randomly assigned
246 with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydroge
247 an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or less, white blood cell count
248 ays was 2.17 (95% CI, 0.84-5.62) for an ECOG performance status of 3-4 vs 0-2 and 5.20 (95% CI, 2.70-
249 inoma with clear cell histology, a Karnofsky Performance Status of 70% or more, and measurable diseas
250 with lower OS were a Ki-67 of more than 10%, performance status of at least 1, previous chemotherapy
253 d after docetaxel treatment with a Karnofsky performance status of more than 70% and who were fit for
254 e, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, alpha-fetoprotein concen
255 rs v1.1), Eastern Cooperative Oncology Group performance statuses of 0 or 1, and available tumour sam
256 ymphoma; Eastern Co-operative Oncology Group performance statuses of 0-2; bidimensionally measurable
257 group had a higher proportion of women with performance statuses of 1 to 2 compared with those who u
259 Results Both models included age, Zubrod performance status, pack-years, education, p16 status, a
262 Identifying how the prognostic impact of performance status (PS) differs according to indication,
265 se pain), Eastern Cooperative Oncology Group performance status (range, 0-4; higher scores indicate w
266 between matched patients regarding age, sex, performance status, receipt of preoperative treatment, e
267 mance status score of less than 3 (Karnofsky Performance Status score >40) were registered to receive
268 enrolment (east Asia vs rest of world), ECOG performance status score (0 vs 1), histology (squamous v
269 atory; an Eastern Cooperative Oncology Group performance status score 0 or 1; and adequate organ func
270 disease, Eastern Cooperative Oncology Group performance status score 1 or 2, systemic inflammation,
271 d with an Eastern Cooperative Oncology Group performance status score of 0 or 1 were randomly assigne
272 sease, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and a measurable les
273 an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 mo
275 a were an Eastern Cooperative Oncology Group performance status score of 0 or 1; a normal left ventri
279 cluded an Eastern Cooperative Oncology Group performance status score of 2 or less and adequate haema
280 se and an Eastern Cooperative Oncology Group performance status score of 2 or less, enrolled from 25
281 mes were aged 18 years or older with an ECOG performance status score of 2 or lower, and were relapse
283 our or lymphoma, and a Lansky Play/Karnofsky Performance status score of 50 or higher, received intra
284 =16 years) or Karnofsky (patients >16 years) performance status score of at least 50, and a new diagn
286 r) and an Eastern Cooperative Oncology Group performance status score of less than 3 (Karnofsky Perfo
290 ndex (IPI) components (ie, age, tumor stage, performance status, serum lactate dehydrogenase concentr
291 ortality in Status 1A included life support, performance status, severe coagulopathy, severe hypo or
294 men, and Eastern Cooperative Oncology Group performance status was 0 for 29% of patients and 1 for 7
300 ed a standard of care for patients with good performance status who plan to receive WBRT for brain me